Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042109 (urticaria)
 6,569 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The eosinophil has characteristic granules containing a variety of mediators that may be important in the pathogenesis of cutaneous disease. Although numerous cutaneous diseases may be associated with tissue infiltration with eosinophils, in very few disorders, including Wells' syndrome, angiolymphoid hyperplasia with eosinophilia, and granuloma faciale, does the pattern of eosinophil infiltration contribute to the characteristic histopathologic picture. Immunofluorescence studies demonstrating eosinophil degranulation in the skin, particularly in urticaria and angioedema, have provided evidence to support a role for eosinophil mediators in the pathogenesis of certain cutaneous diseases.
 ...
PMID:The eosinophil. 307 52

Causes and precipitating factors for systemic necrotizing angiitis (NA) with asthma were sought in 43 patients, focusing on a history of vaccination and desensitization. Mean age of patients was 43.2 years. Diagnosis was based on histopathologic findings in 25 patients, arteriography in 2, and clinical criteria in 16. History of allergic manifestations (asthma, rhinitis, eczema, urticaria) was present in the family of 19 patients. Forty-two patients presented with asthma before development of NA and 23 of them were treated with steroids. Nineteen subjects gave a history of desensitization and 5 of vaccination in the 4 weeks preceding the disease. The main symptoms of NA were asthma in 43, fever in 25, weight loss in 31, peripheral neuropathy in 29, cutaneous signs in 25, digestive signs in 16 (abdominal pain, digestive bleeding, bowel perforation), noninfectious pneumopathy with pulmonary infiltrates in 33. Eosinophilia was 8,212 +/- 6,214/mm3. Antigen HBs was found in 2 of 30 patients. Prognosis of NA with asthma was good in 15 patients who recovered completely from the disease. Seven patients died and the other patients improved but remained under treatment. The survival curve showed that 75% of patients were alive after 60 months. Our findings suggest that different causes can be considered responsible for NA, and that, in cases of NA with asthma, there is reason to consider vaccination and desensitization as precipitating factors.
 ...
PMID:Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. 310 93

This study was designed to establish IgE values in different allergic diseases in an Israeli population and healthy controls. The geometric mean IgE in the control group was 41 IU/mL (range = 15 to 111 IU/mL) and in the atopic group 142 IU/mL (range = 36 to 556 IU/mL). The highest values were found in patients with asthma plus allergic rhinitis plus atopic dermatitis and asthma plus atopic dermatitis. The lowest values were from patients with urticaria. There was a gradual increase in IgE levels from 4 to 10 years and then a gradual decrease. IgE was significantly higher in males, particularly in the 21 to 40-year age group and above 60 years. There was no difference in IgE levels in the various ethnic groups. There was a correlation between IgE levels and the number of positive skin tests. Peripheral eosinophilia was found in one-third of the patients with low IgE and in 2/3 of the patients with IgE above 500 IU/mL. An IgE of 120 IU/mL or more was found in 56% of patients with asthma in addition to other atopic diseases. Only 10% of normal controls had an IgE value of 120 IU/mL or more. These results are similar to those reported from European and North American countries.
 ...
PMID:IgE values in the allergic and healthy Israeli population. 340 Aug 97

Asthma, aspirin intolerance and nasal polyps form a triad of aspirin-induced asthma (AIA). Eighteen cases, 6 males and 12 females, who complained of asthma attacks and/or rhinorrhea after ingestion of non-steroidal anti-inflammatory drugs were encountered over several years. The mean age of onset was 32.1 for asthma and 25.4 for rhinitis. Asthma was found in all of the 18 cases and nasal polyps in 13 cases (72.2%). The polyps were recurrent and 7 patients had undergone polypectomies. Urticaria was seen in 44.4% and sinusitis diagnosed by X-ray in 81.8%. Sensitivity to at least one allergen was found in 7 out of 9 cases (77.8%) and 6 out of 11 cases (54.5%) gave results positive for RAST. Eosinophilia was seen in 14 out of 16 patients (87.5%). The pathogenesis of AIA is obscure but is probably related to inhibition of prostaglandin biosynthesis. We concluded that AIA is not a rare disease in Japan either, and the studies for eosinophilia may be useful for elucidation of the pathogenesis of AIA and nasal polyps.
 ...
PMID:Aspirin-induced asthma and nasal polyps. 346 81

The relative safety of imipenem/cilastatin for 3470 patients was reviewed to see if the safety profile was similar to that seen for the first 1723 patients treated. The most common clinical adverse experiences were local ones related to the site of intravenous infusion. Gastrointestinal adverse experiences included nausea, vomiting, or diarrhoea. The frequency of pseudomembranous colitis was low (0 X 1%). The most common central nervous system abnormality was seizure. The most common background factor was central nervous system abnormality including prior history of seizure. Dermatological adverse experiences included rash, pruritus and urticaria. Bleeding and decreased renal function were uncommon. The most common laboratory changes included transient increased liver function values, eosinophilia, positive Coombs' test (not associated with haemolysis) and increased platelets. The current clinical and laboratory safety data are similar to those obtained in the early part of the clinical trials.
 ...
PMID:The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. 346 94

We have attempted to clinically define the therapeutic usefulness of ceftizoxime suppository (CZX-S) in children with bacterial pneumonia, in a randomized trial. Intravenous injection of ceftizoxime (CZX) was used as the control. The results are summarized below. Subjects were inpatients with bacterial pneumonia, ranging in age from 9 months to 7 years and 10 months. As a rule, the daily dose was either four 250 mg (in potency) suppositories given at 6-hour intervals or 60 mg/kg body weight intravenous CZX (control) given in 4 injections at 6-hour intervals over a period of 7 days. The number of children in the study was 67. These children were divided into 2 dosage groups (suppository, 35; injection, 32) with matching pretreatment background factors. The severity of the target disease in the majority of the children was "moderate". The rate of therapeutic effectiveness was 97.1% for the suppository and 93.8% for the injection, and did not differ significantly between the 2 groups. Rates of efficacy by severity, presence or absence of underlying diseases, daily dose and/or complications were high without exception, and did not differ significantly between the 2 groups. Eradication rates for causative microorganisms, as studied in 16 children of each group, were both 93.8%. The 2 most frequently isolated causative organisms were Haemophilus influenzae and Streptococcus pneumoniae. Side effects were examined for 36 children of each group. The frequency of side effects did not differ significantly between the suppository group (2 with diarrhea and 1 with abdominal pain) and the injection group (1 with urticaria), and 8.3% and 2.8%, respectively. The frequency of abnormal laboratory test findings differed significantly (P less than 0.01) with respect to eosinophilia which occurred in 7 (20.6%) of the injected subjects but was not encountered in the subjects treated with suppositories. Other abnormal laboratory findings included thrombocytosis in 3 (14.3%) of the injection group and increased GOT in 1 (3.2%) of the suppository group. The suppository formulation of CZX appears to be a highly useful substitute for the injectable form, and should find a special use in children whose treatment with injections experiences some difficulty.
 ...
PMID:[A comparative, well-controlled study of ceftizoxime suppository against ceftizoxime intravenous injection in infantile acute pneumonia]. 353 67

Utilizing affinity chromatography-purified antibody to the eosinophil granule major basic protein and formalin-fixed paraffin embedded tissue, we investigated the localization of major basic protein by immunofluorescence in twenty-four skin biopsy specimens from ten patients with pressure urticaria. Fourteen of twenty-four biopsy specimens were obtained from spontaneously occurring urticarial lesions of 4 to 48 hours' duration, and ten of the twenty-four specimens were from dermographometer-induced lesions that had been present from 40 minutes to 24 hours. Twenty-one of twenty-four biopsy specimens showed extracellular fluorescence of eosinophil granule major basic protein within the dermis. The extent and intensity of extracellular staining were not related to the presence or degree of tissue eosinophilia. Serial section controls from each block were stained with protein A purified rabbit IgG and were negative. Previous immunofluorescence studies have demonstrated deposition of major basic protein in lesions of chronic idiopathic urticaria, episodic angioedema, and facial edema. Major basic protein causes release of histamine from human basophils and induces wheal-and-flare reactions on intradermal injection. The present observations add further evidence to support a role for eosinophil mediators, particularly major basic protein, in the pathogenesis of cutaneous disease characterized by edema.
 ...
PMID:Extracellular deposition of eosinophil granule major basic protein in pressure urticaria. 354 18

We report a case of exercise induced joint effusion with synovial fluid (SF) eosinophilia of 9,540/mm3 in a patient with delayed pressure urticaria. The SF eosinophilia was an acute but transient event associated with some evidence of local complement activation. Histologic assessment revealed a normal synovial membrane but with no detectable intact mast cells. These observations suggest that mast cells and eosinophils acting in concert can cause joint inflammation.
 ...
PMID:Acute synovial fluid eosinophilia associated with delayed pressure urticaria: a role for mast cells? 359 8

A 49-year-old patient presented with urticaria, vomiting, diarrhea and peripheral eosinophilia. A histological diagnosis of eosinophilic gastroenteritis was made. Within 3 weeks of admission a highly papillary adenocarcinoma of the right ovary was diagnosed. The gastrointestinal symptoms and the eosinophilia disappeared after partial resection of the tumor and chemotherapy. A possible relationship between cancer, eosinophilia and eosinophilic gastroenteritis is discussed.
 ...
PMID:Malignant tumor masquerading as eosinophilic gastroenteritis. 362 86

The acquired form of cold induced urticarial syndrome can be found associated with serum cryoproteins, in idiopathic form (generally IgE mediated) and transitory forms associated with other factors. The viral infections, specially infectious mononucleosis and hepatitis B can cause urticaria, mostly chronic, although infrequently produces cold urticaria. We present a case of a 13 year old patient with history suggestive of cold urticaria wherein we have found the existence of a mixed polyclonal cryoglobulinemia, IgG-IgA (exceptionally associated) and serologic markers of hepatitis B, HBsAb and HBsAb (the last being suggestive of a recent infection) 3 months from the urticaria, without recent or past history of hepatitis B infection. We also observed an elevated total serum IgE and peripheral blood eosinophilia. The provocation test presented an evolution similar to the cryoglobulinemia and markers of hepatitis B (after 18 months were negative) but serum IgE and eosinophilia remain elevated until the present time. All of this make us think that the patient could have suffered a subclinical form of hepatitis B which triggered off a cryoglobulinemia, presenting as cold urticaria.
 ...
PMID:[Cold urticaria associated with serologic markers of hepatitis B and cryoglobulinemia]. 366 57


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>